Michelle Arbesman
Research Subjects
Michelle Arbesman has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
- Alan Shen
Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, Ohio
23 shared publications - Brandon Bungo
Cleveland Clinic Taussig Cancer Institute, Cleveland, Ohio
23 shared publications - Brian Gastman
Department of Plastic Surgery Cleveland Clinic Cleveland Ohio USA
23 shared publications - C. Marcela Diaz-Montero
Cleveland Clinic 7 Cleveland, OH
23 shared publications - Jennifer Susan Ko
Department of Pathology Cleveland Clinic Cleveland Ohio USA
23 shared publications - Joshua Arbesman
Cleveland Clinic Cleveland Ohio USA
23 shared publications
Latest Publications
- Open Access
- 1 February 2024
- Published by American Association for Cancer Research (AACR)
Table S4 from Clinical and Immunologic Features of Germline Pathogenic Variant–Positive Patients with Melanoma
Cox proportional hazards analysis of MSS.
- 1 February 2024
- Published by American Association for Cancer Research (AACR)
Open AccessTable S4 from Clinical and Immunologic Features of Germline Pathogenic Variant–Positive Patients with Melanoma
Cox proportional hazards analysis of MSS.
- Open Access
- 1 February 2024
- Published by American Association for Cancer Research (AACR)
Table S6 from Clinical and Immunologic Features of Germline Pathogenic Variant–Positive Patients with Melanoma
Germline variants in TCGA vs manuscript cohort.
- 1 February 2024
- Published by American Association for Cancer Research (AACR)
Open AccessTable S6 from Clinical and Immunologic Features of Germline Pathogenic Variant–Positive Patients with Melanoma
Germline variants in TCGA vs manuscript cohort.
- Open Access
- 1 February 2024
- Published by American Association for Cancer Research (AACR)
Table S1 from Clinical and Immunologic Features of Germline Pathogenic Variant–Positive Patients with Melanoma
Eligibility criteria amongst patient cohort.
- 1 February 2024
- Published by American Association for Cancer Research (AACR)
Open AccessTable S1 from Clinical and Immunologic Features of Germline Pathogenic Variant–Positive Patients with Melanoma
Eligibility criteria amongst patient cohort.
- Open Access
- 1 February 2024
- Published by American Association for Cancer Research (AACR)
Table S2 from Clinical and Immunologic Features of Germline Pathogenic Variant–Positive Patients with Melanoma
GPV categories broken up by HRD, Non-HRD, and MMR.
- 1 February 2024
- Published by American Association for Cancer Research (AACR)
Open AccessTable S2 from Clinical and Immunologic Features of Germline Pathogenic Variant–Positive Patients with Melanoma
GPV categories broken up by HRD, Non-HRD, and MMR.
- Open Access
- 1 February 2024
- Published by American Association for Cancer Research (AACR)
Data from Clinical and Immunologic Features of Germline Pathogenic Variant–Positive Patients with Melanoma
Purpose:Malignant melanoma represents the most lethal skin cancer with germline predispositions thought to comprise 10% to 15% of all melanoma cases. No studies to date examine the immunologic features that may differentiate survival differences between germline pathogenic variant (gPV)–positive patients with melanoma from gPV-negative patients with melanoma.Experimental Design:Adult patients with melanoma and clinical characteristics suggesting hereditary predisposition to cancer were prospectively recruited to undergo germline testing and flow cytometric analysis of peripheral immune suppressor cells.Results:In this cohort, gPV-positive patients (n = 72) had a significantly improved melanoma-specific survival (MSS) compared with gPV-negative patients (n = 411; HRadj, 0.32; 95% CI, 0.13–0.82; P = 0.01). These survival improvements among gPV-positive patients were most apparent among cutaneous melanoma subtypes (HRadj, 0.12; 95% CI, 0.016–0.86; P = 0.03) and numerically improved in later-stage (IIB–IV) patients (HRadj, 0.34; 95% CI, 0.10–1.11; P = 0.06). Further, gPV-positive patients had a significantly lower level of total circulating PMN-MDSC compared with gPV-negative patients (P = 0.01), which was most apparent in those diagnosed with later stages (IIB–IV) of melanoma (P = 0.009). Finally, a significant upregulation of inflammatory transcriptome signatures in later-stage gPV-positive patients (n = 21) was observed in comparison with gPV-negative patients (n = 173) in the cutaneous melanoma cohort (SKCM) of The Cancer Genome Atlas (TCGA).Conclusions:gPV-positive patients with melanoma exhibit improved MSS in addition to reduced peripheral PMN-MDSC and an enhanced inflammatory microenvironment.
- 1 February 2024
- Published by American Association for Cancer Research (AACR)
Open AccessData from Clinical and Immunologic Features of Germline Pathogenic Variant–Positive Patients with Melanoma
Purpose:Malignant melanoma represents the most lethal skin cancer with germline predispositions thought to comprise 10% to 15% of all melanoma cases. No studies to date examine the immunologic features that may differentiate survival differences between germline pathogenic variant (gPV)–positive patients with melanoma from gPV-negative patients with melanoma.Experimental Design:Adult patients with melanoma and clinical characteristics suggesting hereditary predisposition to cancer were prospectively recruited to undergo germline testing and flow cytometric analysis of peripheral immune suppressor cells.Results:In this cohort, gPV-positive patients (n = 72) had a significantly improved melanoma-specific survival (MSS) compared with gPV-negative patients (n = 411; HRadj, 0.32; 95% CI, 0.13–0.82; P = 0.01). These survival improvements among gPV-positive patients were most apparent among cutaneous melanoma subtypes (HRadj, 0.12; 95% CI, 0.016–0.86; P = 0.03) and numerically improved in later-stage (IIB–IV) patients (HRadj, 0.34; 95% CI, 0.10–1.11; P = 0.06). Further, gPV-positive patients had a significantly lower level of total circulating PMN-MDSC compared with gPV-negative patients (P = 0.01), which was most apparent in those diagnosed with later stages (IIB–IV) of melanoma (P = 0.009). Finally, a significant upregulation of inflammatory transcriptome signatures in later-stage gPV-positive patients (n = 21) was observed in comparison with gPV-negative patients (n = 173) in the cutaneous melanoma cohort (SKCM) of The Cancer Genome Atlas (TCGA).Conclusions:gPV-positive patients with melanoma exhibit improved MSS in addition to reduced peripheral PMN-MDSC and an enhanced inflammatory microenvironment.
- Open Access
- 1 February 2024
- Published by American Association for Cancer Research (AACR)
Table S5 from Clinical and Immunologic Features of Germline Pathogenic Variant–Positive Patients with Melanoma
Multivariable linear regression on PMN-MDSC counts.
- 1 February 2024
- Published by American Association for Cancer Research (AACR)
Open AccessTable S5 from Clinical and Immunologic Features of Germline Pathogenic Variant–Positive Patients with Melanoma
Multivariable linear regression on PMN-MDSC counts.
- Open Access
- 1 February 2024
- Published by American Association for Cancer Research (AACR)
Table S3 from Clinical and Immunologic Features of Germline Pathogenic Variant–Positive Patients with Melanoma
Representativeness of study participants.
- 1 February 2024
- Published by American Association for Cancer Research (AACR)
Open AccessTable S3 from Clinical and Immunologic Features of Germline Pathogenic Variant–Positive Patients with Melanoma
Representativeness of study participants.
- Open Access
- 1 February 2024
- Published by American Association for Cancer Research (AACR)
Table S3 from Clinical and Immunologic Features of Germline Pathogenic Variant–Positive Patients with Melanoma
Representativeness of study participants.
- 1 February 2024
- Published by American Association for Cancer Research (AACR)
Open AccessTable S3 from Clinical and Immunologic Features of Germline Pathogenic Variant–Positive Patients with Melanoma
Representativeness of study participants.
- Open Access
- 1 February 2024
- Published by American Association for Cancer Research (AACR)
Table S4 from Clinical and Immunologic Features of Germline Pathogenic Variant–Positive Patients with Melanoma
Cox proportional hazards analysis of MSS.
- 1 February 2024
- Published by American Association for Cancer Research (AACR)
Open AccessTable S4 from Clinical and Immunologic Features of Germline Pathogenic Variant–Positive Patients with Melanoma
Cox proportional hazards analysis of MSS.
- Open Access
- 1 February 2024
- Published by American Association for Cancer Research (AACR)
Table S1 from Clinical and Immunologic Features of Germline Pathogenic Variant–Positive Patients with Melanoma
Eligibility criteria amongst patient cohort.
- 1 February 2024
- Published by American Association for Cancer Research (AACR)
Open AccessTable S1 from Clinical and Immunologic Features of Germline Pathogenic Variant–Positive Patients with Melanoma
Eligibility criteria amongst patient cohort.